Clinical Study for the Evaluation of Safety and Tolerability of NCP112 Eye Drops — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Clinical Study for the Evaluation of Safety and Tolerability of NCP112 Eye Drops — Stella

Home/Xerophthalmia/

View on ClinicalTrials.gov

Recruiting

Back to Xerophthalmia trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

South Korea

Seoul National University Hospital, Seoul, Daehak-ro, Jongno-gu

Key details

Phase

Early testing

Sponsor

Huons Co., Ltd.

Enrollment target

~60 participants

Started

July 2024

Primary completion

November 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

19 Years – 50 Years

Last updated October 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.